BeiGene, Ltd. (BEIGF)
OTCMKTS
· Delayed Price · Currency is USD
15.95
-3.06 (-16.10%)
At close: Apr 9, 2025
BeiGene Revenue
BeiGene had revenue of $1.12B in the quarter ending March 31, 2025, with 48.64% growth. This brings the company's revenue in the last twelve months to $4.18B, up 51.16% year-over-year. In the year 2024, BeiGene had annual revenue of $3.81B with 54.96% growth.
Revenue (ttm)
4.18B
Revenue Growth
+51.16%
P/S Ratio
6.04
Revenue / Employee
379.62K
Employees
11,000
Market Cap
25.20B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.81B | 1.35B | 54.96% |
| Dec 31, 2023 | 2.46B | 1.04B | 73.65% |
| Dec 31, 2022 | 1.42B | 239.64M | 20.37% |
| Dec 31, 2021 | 1.18B | 867.41M | 280.83% |
| Dec 31, 2020 | 308.87M | -119.34M | -27.87% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo Inc. | 1.73B |
| Veradigm | 588.02M |
| Tian'an Technology Group | 1.78M |
| Glass House Brands | 200.90M |
| Elite Pharmaceuticals | 70.00M |
| Northwest Biotherapeutics | 1.38M |
| BioStem Technologies | 301.83M |
| American Oncology Network | 1.76B |